Pharmion licenses from Methylgene, Novartis licenses from Celgene, Moffitt, MD Anderson, Dnaprint, Harvard, St. Jude's are in alliance and all working with these drugs and others. This post could be 10X the size it is.
About Pharmion
Pharmion is a biopharmaceutical company focused on acquiring, developing and commercializing innovative products for the treatment of hematology and oncology patients in the U.S., Europe and additional international markets. Pharmion has a number of products on the market including the world's first approved epigenetic therapy, Vidaza(R); a DNA demethylating agent. For additional information about Pharmion, please visit the company's website at http://www.pharmion.com.
CELGENE: The company's commercial programs include pharmaceutical sales of THALOMID(thalomide) and ALKERAN(melphalan), a licensing agreement with Novartis for FOCALIN and the entire RITALIN family of drugs.
Pharmion to Present Clinical Data on Commercial and Pipeline Products at 2007 American Society of Clinical Oncology (ASCO) Meeting
Phase I/II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor MGCD0103 in combination with azacitidine in patients (pts) with high-risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) -- G. Garcia-Manero, MD, MD Anderson Cancer Center; Abstract #7062; June 2, 2007; 8:00am-12:00pm; McCormick Convention Center, S Hall A2
A Phase I study of MGCD0103 given as a twice weekly oral dose in patients with advanced leukemias or myelodysplastic syndromes (MDS) -- J. Lancet, MD, H. Lee Moffitt Cancer Center; Abstract #2516; June 4, 2007; 2:00-6:00pm; McCormick Convention Center, S102a
Blood. 2007 Jan 30; : 17264302 Ancestry and pharmacogenetics of antileukemic drug toxicity. [My paper] Shinji Kishi , Cheng Cheng , Deborah French , Deqing Pei , Soma Das , Edwin H Cook , Nobuko Hijiya , Carmelo Rizzari , Gary L Rosner , Tony Frudakis , Ching-Hon Pui , William E Evans , Mary V Relling
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. [My paper] Cheri E Klein , Helen Kastrissios , Antonius A Miller , Donna Hollis , Daohai Yu , Gary L Rosner , David L Grinblatt , Richard A Larson , Mark J Ratain
J Clin Oncol. 2006 Mar 27; : 16567769 Prospective Evaluation of the Relationship of Patient Age and Paclitaxel Clinical Pharmacology: Cancer and Leukemia Group B (CALGB 9762). [My paper] Stuart M Lichtman , Donna Hollis , Antonius A Miller , Gary L Rosner , Chris A Rhoades , Eric P Lester , Frederick Millard , John Byrd , Stephen A Cullinan , D Marc Rosen , Robert A Parise , Mark J Ratain , Merrill J Egorin
Melphalan/Topotecan Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Melphalan/Topotecan (MT) response in multiple myeloma patients. MT is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting MT response could help minimize the likelihood of multiple myeloma relapse.
Xeleri/Xelox Through collaboration with the Moffitt Cancer Research Center in Tampa, FL, we are investigating the genetic basis of Xeleri/Xelox response for colon cancer patients. Xeleri/Xelox is a chemotherapy that prevents the cell division that tumors need to grow but for some patients, normal doses do not elicit the desired effect. A genetic test for predicting Xeleri/Xelox response could help minimize the likelihood of colon cancer relapse.
Q: What will be the key steps to achieve the goal of dramatically reducing acute and long-term morbidity associated with pediatric cancer treatment? A: Our Cancer Prevention and Control Program and the ACT Clinic provide a strong platform for these advances. When this is coupled with new knowledge emerging from efforts like the human genome project, pharmacogenomics, biotechnology and informatics, it may soon be possible to further individualized treatments to enhance efficacy while minimizing the risk of toxicity, especially in children we can identify as being predisposed to toxicities. That’s our goal, and we think it’s realistic over the next decade.
Market Data 
Markets 
AI
